The DOI matches its Crossref record; 123 of the 124 references it cites were found in a registry or an index.
The Role of GLP-1 in Neuronal Activity and Neurodegeneration
Abstract
Type 2 diabetes has been identified as a risk factor for Alzheimer's disease (AD). The underlying mechanism behind this unexpected link is most likely linked to the observed desensitization of insulin receptors in the brain. Insulin acts as a growth factor in the brain and supports neuronal repair, dendritic sprouting, and differentiation. Several drugs have been developed to treat type 2 diabetes which re-synthesize insulin receptors and may be of use to prevent neurodegenerative developments in AD. The incretin glucagon-like peptide-1 (GLP-1) is a hormone that facilitates insulin release under high blood sugar conditions. Interestingly, GLP-1 also has very similar growth factor like properties as insulin, and has been shown to protect neurons from toxic effects. In preclinical studies, GLP-1 and longer lasting analogues reduce apoptosis, protect neurons from oxidative stress, induce neurite outgrowth, protect synaptic plasticity and memory formation from the detrimental effects of β-amyloid, and reduce plaque formation and the inflammation response in the brains of mouse models of AD. An advantage of GLP-1 is that it does not affect blood sugar levels in nondiabetic people. Furthermore, recent research has shown that some GLP-1 analogues can cross the blood-brain barrier, including two that are on the market as a treatment for type 2 diabetes. Therefore, GLP-1 analogues show great promise as a novel treatment for AD or other neurodegenerative conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In AD, GLP-1(7-36) amide inhibits IL-1β transcription and prevents cognitive dysfunction, amyloid precursor protein synthesis, and cell death.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [426]
In the citing paper
“It also enhances learning and memory by promoting long-term potentiation (LTP).425,426”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [426]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“The increased levels of ATP affect ATP sensitive Kþ channels in the cell membrane, which will reduce repolarization of the membrane, and therefore increase depolarization and enhance insulin vesicle release (Baggio and Drucker, 2007; Doyle and Egan, 2007; Perry et al., 2003).”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Recently, it was shown that insulin receptors in the brain are desensitized in AD patients, and this condition has been named “type 3 diabetes” by some authors (Lester-Coll et al., 2006; Steen et al., 2005).”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
A Family of cAMP-Binding Proteins That Directly Activate Rap1
Kawasaki, H., Springett, G. M., Mochizuki, N., Toki, S., Nakaya, M., Matsuda, M., Housman, D. E., & Graybiel, A. M. (1998) · Science · doi:10.1126/science.282.5397.2275 · Cited by 1,362
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 1×
“This effect ismost remarkable, and underlines the fact that b-amyloid has numerous independent effects on cell physiology; some ofwhichmay occur very early on inAD, long before amyloid aggregates appear and neuronal death is observed (Gong et al., 2003; Townsend et al., 2006).”
BackgroundNagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 1×
“Increase of BDNF levels, when administered after disease onset, reversed synapse loss, improved synaptic plasticity, and restored learning abilities of a mouse model of AD (Nagahara et al., 2009; Poon et al., 2009).”
BackgroundAβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
Self-citationIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950
Roles of N-Type and Q-Type Ca 2+ Channels in Supporting Hippocampal Synaptic Transmission
Wheeler, D. B., Randall, A., & Tsien, R. W. (1994) · Science · doi:10.1126/science.7832825 · Cited by 949
Cited by
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“425,426 In a murine model of AD, the administration of GLP-1RAs effectively reduced the levels of pathological markers associated with AD.”
BackgroundBlázquez, E., Velázquez, E., Hurtado-Carneiro, V., & Ruiz-Albusac, J. M. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00161 · Cited by 491
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“These neurons project to the thalamus, hypothalamus and cortical regions, and induce the release of GLP-1 by various stimuli in a mechanism similar to L-cells of the small intestine (30, 31, 240, 243).”
BackgroundDrug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Metadata
- Authors
- Hölscher, C.
- Affiliations
- University of Ulster (GB)
- Corresponding author
- Hölscher, Christian
- ORCID
- Hölscher, Christian
- Venue
- Vitamins & Hormones
- Publisher
- Elsevier
- Published
- 2010
- Volume
- 84
- Pages
- 331-354
- ISSN
- 0083-6729 (ISSN-L)
- OpenAlex
- W1601982370
- Cited by
- 74
- References
- 124
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 4 · 2019: 1 · 2018: 7 · 2017: 7 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 6 · 2012: 11
- FWCI
- 22.52
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Vitamins and hormones (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- glucagon-like peptide-1, GLP-1 analogues, Alzheimer's disease, neurodegeneration, type 2 diabetes, neuroprotection, amyloid-beta, neuroinflammation, blood-brain barrier, synaptic plasticity, memory formation, oxidative stress, apoptosis, neurite outgrowth
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Diabetes Mellitus, Type 2, Humans, Nerve Degeneration, Receptor, Insulin, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of GLP-1 in Neuronal Activity and Neurodegeneration. https://app.cochat.ai/papers/10.1016/b978-0-12-381517-0.00013-8
- The paper
- Hölscher, C. (2010). The Role of GLP-1 in Neuronal Activity and Neurodegeneration. Vitamins & Hormones. https://doi.org/10.1016/b978-0-12-381517-0.00013-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.